Year 2021 / Volume 113 / Number 4
Letter
Acute hepatocellular drug-induced liver injury probably caused by doxazosin

301-302

DOI: 10.17235/reed.2020.7268/2020

Javier Jiménez Sánchez, Lidia Serrano Díaz, Juan José Martínez Crespo,

Abstract
Drug-induced liver injury (DILI) is a diagnostic challenge, due to the hepatotoxic potential of drugs, herbs and dietary supplements, the variety of pathological phenotypes and the absence of specific biomarkers.
Share Button
New comment
Comments
No comments for this article
References
1. LiverTox: Clinical and Research Information on DrugInduced Liver Injury [Internet]. Doxazosin. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012- [actualizado 8 de enero de 2018; consultado 13 de marzo de 2020]. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK548718/
2. Agencia Española de Medicamentos y Productos Sanitarios [sede Web]. Fecha técnica Doxazosina 2 mg. Madrid: Agencia Española de Medicamentos y Productos Sanitarios; 2016 [consultado el 13 de marzo de 2020]. Disponible en: https://cima.aemps.es/cima/dochtml/ft/63789/FT_63789.html
3. Cicek T, Gokturk HS, Unler GK. Acute hepatocellular drug induced liver injury probably by alfuzosin. Case Rep Urol. 2015: 101062.
4. Danan G, Benichou C. Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: application to druginduced liver injuries. J Clin Epidemiol. 1993; 46(11): 1323-1330.
5. Andrade RJ, Aithal GP, Bjornsson ES, et al. EASL Clinical practices guidelines: Drug-induced liver injury. J Hepatol. 2019; 70(6): 1222-1261.
Related articles

Letter

Drug-induced liver injury associated to red yeast rice

DOI: 10.17235/reed.2023.9797/2023

Letter

Hepatitis B virus reactivation after ibrutinib treatment

DOI: 10.17235/reed.2023.9587/2023

Letter

Autoimmune hepatitis after SARS-C¬¬oV-2 vaccination

DOI: 10.17235/reed.2023.9579/2023

Editorial

New actors come into play against hepatitis delta

DOI: 10.17235/reed.2022.9050/2022

Letter

DRESS syndrome secondary to carbamazepine

DOI: 10.17235/reed.2022.8977/2022

Letter

COVID-19 vaccine and autoimmune hepatitis

DOI: 10.17235/reed.2022.8837/2022

Editorial

Orthohepevirus C as causal agent of acute hepatitis in Spain

DOI: 10.17235/reed.2022.8993/2022

Letter

SARS-CoV-2 vaccine, a new autoimmune hepatitis trigger?

DOI: 10.17235/reed.2022.8820/2022

Letter

Cefditoren-induced hepatitis

DOI: 10.17235/reed.2022.8801/2022

Letter

AMA-positive hepatitis induced by the SARS-CoV-2 vaccine.

DOI: 10.17235/reed.2022.8533/2021

Letter

A case of COVID-19 with concomitant infection with hepatitis A

DOI: 10.17235/reed.2021.8372/2021

Editorial

Cases of liver disease lost in the health system: a call to action

DOI: 10.17235/reed.2021.8316/2021

Original

Active search for hepatitis C patients in primary care

DOI: 10.17235/reed.2021.8067/2021

Letter

Autoimmune hepatitis triggered by COVID-19

DOI: 10.17235/reed.2021.8045/2021

Digestive Diseases Image

Emphysematous hepatitis: a very rare entity with a poor prognosis

DOI: 10.17235/reed.2021.7795/2021

Original

Hepatitis C in homeless people: reaching a hard-to-reach population

DOI: 10.17235/reed.2021.7737/2020

Editorial

Screening guide for hepatitis C virus infection in Spain

DOI: 10.17235/reed.2020.7728/2020

Letter

Acute hepatitis due to olmesartan: an uncommon entity

DOI: 10.17235/reed.2020.7236/2020

Special Article

Strategy for the Elimination of Hepatitis C in Cantabria

DOI: 10.17235/reed.2020.7108/2020

Editorial

Reflex testing. A key tool for the elimination of hepatitis C

DOI: 10.17235/reed.2020.7201/2020

Letter

Candesartan-induced cholestatic hepatitis: a case report

DOI: 10.17235/reed.2020.6988/2020

Original

A new pattern in hepatitis A virus infection in an urban population

DOI: 10.17235/reed.2020.6526/2019

Original

Quality of life study in asymptomatic patients with hepatitis C

DOI: 10.17235/reed.2019.6339/2019

Letter

Acute seronegative hepatitis C: two case reports

DOI: 10.17235/reed.2019.5921/2018

Case Report

Apixaban-induced liver injury

DOI: 10.17235/reed.2018.5877/2018

Case Report

Sarcoidosis onset simulating a unique hepatic metastasis

DOI: 10.17235/reed.2018.5553/2018

Letter to the Editor

Autoimmune hepatitis as a complication of common variable immunodeficiency

DOI: 10.17235/reed.2018.5280/2017

Letter to the Editor

The clinical challenge of chronic Q fever with isolated liver involvement

DOI: 10.17235/reed.2017.4633/2016

Case Report

The clinical extremes of autoimmune cholangitis

DOI: 10.17235/reed.2017.4167/2015

Case Report

Glycogenic hepatopathy in young adults: a case series

DOI: 10.17235/reed.2016.3934/2015

Citation tools
Jiménez Sánchez J, Serrano Díaz L, Martínez Crespo J. Acute hepatocellular drug-induced liver injury probably caused by doxazosin. 7268/2020


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1058 visits.
This article has been downloaded 187 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 15/05/2020

Accepted: 09/06/2020

Online First: 20/11/2020

Published: 07/04/2021

Article revision time: 19 days

Article Online First time: 189 days

Article editing time: 327 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology